FDA approves ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA)

ThromboGenics NV (Euronext Brussels: THR), a Belgian based ophthalmic biotech company has announced the regulatory approval by the US Food and Drugs Administration (FDA) of its ocriplasmin therapy for the treatment of symptomatic VMA. The new drug, expected to launch in the US in January 2013 under the trade name “Jetrea”, is scheduled to be the first pharmacological agent to be approved for VMA. The new new drug will aim to replace vitrectomy as the first-line treatment for VMA, related traction and macular hole.